Full Title
Phase 1 Trial of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RP-1664 in Participants with Advanced Solid TumorsPurpose
Researchers want to find the best dose of RP-1664 to treat advanced solid tumors with certain genetic mutations (changes). RP-1664 blocks a protein called PLK4, which is involved in cancer cell growth. The genetic mutation in your cancer may affect how your cancer responds to RP-1664. This drug is taken orally (by mouth).
Who Can Join
To join this study, there are a few conditions. You must:
- Have an advanced solid tumor that keeps growing even with standard therapy or for which no standard therapy exists.
- Have recovered from the serious side effects of prior treatments before taking RP-1664.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 12 or older.
Contact
For more information or to see if you can join this study, please call Dr. Ezra Rosen’s office at 646-888-4226.
Protocol
24-080
Phase
Phase I (phase 1)
Investigator
Co-Investigators
Diseases
ClinicalTrials.gov ID
NCT06232408